Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open-label, 48-week extension study

2019

Background Tofacitinib is an oral, small molecule Janus kinase inhibitor that is being investigated for inflammatory bowel disease.

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

14

References

19

Citations